In this study released in the Journal for ImmunoTherapy of Cancer, authors depicted the association between the enrichment of Tumor-Associated Macrophages (TAMs) in the Tumor Micro Environment (TME) of Non-Small Cell Lung Cancer (NSCLC) and the resistance to immunotherapy, regardless of the programmed death ligand 1 status.
Using our GeoMx Digital Spatial Profiling (DSP) capacities, authors showed that the TAM recruitment/polarization was driven by the upregulation of CD27, ITGAM, and CCL5 gene expression within the tumor compartment. They finally underlined the complexity of the CSF1R pathway and set aside the hypothesis of its use as a target to improve Inhibitor Checkpoint Blockers (ICB) efficacy.
The article:
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. PMID: 35618288; PMCID: PMC9125754.
https://pubmed.ncbi.nlm.nih.gov/35618288